Cibles Thérapeutiques, INSERM U940, Institut de Génétique Moléculaire, Université Paris 7, Hôpital St. Louis, Paris, France.
PLoS Pathog. 2010 Oct 14;6(10):e1001151. doi: 10.1371/journal.ppat.1001151.
Viruses are known to employ different strategies to manipulate the major histocompatibility (MHC) class I antigen presentation pathway to avoid recognition of the infected host cell by the immune system. However, viral control of antigen presentation via the processes that supply and select antigenic peptide precursors is yet relatively unknown. The Epstein-Barr virus (EBV)-encoded EBNA1 is expressed in all EBV-infected cells, but the immune system fails to detect and destroy EBV-carrying host cells. This immune evasion has been attributed to the capacity of a Gly-Ala repeat (GAr) within EBNA1 to inhibit MHC class I restricted antigen presentation. Here we demonstrate that suppression of mRNA translation initiation by the GAr in cis is sufficient and necessary to prevent presentation of antigenic peptides from mRNAs to which it is fused. Furthermore, we demonstrate a direct correlation between the rate of translation initiation and MHC class I antigen presentation from a certain mRNA. These results support the idea that mRNAs, and not the encoded full length proteins, are used for MHC class I restricted immune surveillance. This offers an additional view on the role of virus-mediated control of mRNA translation initiation and of the mechanisms that control MHC class I restricted antigen presentation in general.
病毒被认为采用不同的策略来操纵主要组织相容性(MHC)I 类抗原呈递途径,以避免免疫系统识别感染的宿主细胞。然而,病毒通过供应和选择抗原肽前体的过程来控制抗原呈递的机制尚不清楚。 Epstein-Barr 病毒(EBV)编码的 EBNA1 在所有 EBV 感染的细胞中表达,但免疫系统无法检测和破坏携带 EBV 的宿主细胞。这种免疫逃逸归因于 EBNA1 中的甘氨酸-丙氨酸重复(GAr)能够抑制 MHC 类 I 限制的抗原呈递。本文作者证明,GAr 在顺式中抑制 mRNA 翻译起始足以且必需防止融合的 mRNA 中的抗原肽呈递。此外,作者还证明了翻译起始率与特定 mRNA 上 MHC I 类抗原呈递之间存在直接相关性。这些结果支持这样一种观点,即用于 MHC I 类限制免疫监视的是 mRNA,而不是编码的全长蛋白。这为病毒介导的 mRNA 翻译起始控制以及 MHC I 类限制抗原呈递的一般机制的作用提供了另一种观点。